-
Innovative TCM Compound Binafuxi Granules Approved for Marketing by China NMPA
2025-06-11
Recently, the Class 1.1 innovative traditional Chinese medicine (TCM) Compound Binafuxi Granules of Xinjiang Yinduolan Uighur Medicine Co., Ltd. is approved for marketing by China NMPA.
-
Announcement of the National Medical Products Administration and National Health Commission on Issuing the 2025 Edition of the Pharmacopoeia of the People’s Republic of China (No. 29, 2025)
2025-06-11
According to the Drug Administration Law of the People's Republic of China, the Pharmacopoeia of the People's Republic of China (2025 Edition) (hereinafter referred to as Chinese Pharmacopoeia) has been reviewed and approved by the Plenary Meeting of the Executive Committee of the 12th Chinese Pharmacopoeia Commission.
-
NMPA Announcement on Matters Related to the Implementation of the 2025 Edition of the Pharmacopoeia of the People's Republic of China (No. 32, 2025)
2025-06-11
The 2025 Edition of the Pharmacopoeia of the People's Republic of China (hereinafter referred to as the Chinese Pharmacopoeia) has been issued by Announcement No. 29, 2025 of the National Medical Products Administration and the National Health Commission and shall come into force as of October 01, 2025.
-
Zolbetuximab for Injection Approved for Marketing by China NMPA
2025-06-11
Recently, the Zolbetuximab for Injection (trade name: 威络益/VYLOY) of Astellas Pharma Europe B.V. is approved for marketing by China NMPA.
-
Tagitanlimab Injection Approved for Marketing by China NMPA
2025-06-11
Recently, the Tagoliticimab Injection (trade name: 科泰莱) of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is approved for marketing by China NMPA.
-
Amimestrocel Injection Approved with Conditions for Marketing by China NMPA
2025-06-11
Recently, the Amimestrocel Injection (trade name: 睿铂生) of Platinumlife Biotechnology (Beijing) Co., Ltd. is approved with conditions through the priority review and approval procedure by China NMPA.
